Dermata Therapeutics, Inc. DRMA
mean Dermata Therapeutics, Inc. unless stated otherwise or the context otherwise indicates.
to the development and commercialization of products that address common and underserved skin conditions. Dermata initially was founded
with a focus on researching and developing prescription products subject to the FDA approval process. As part of this focus, we had one
lead asset, referred to as XYNGARI, also known as DMT310, which we had been studying in clinical trials for the treatment of moderate-to-severe
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M | $1.6M | — |
| SG&A | $4.8M | $4.3M | $4.0M | $4.0M | $4.4M | $1.6M | — |
| Total operating expenses | $7.8M | $12.5M | $8.0M | $9.7M | — | — | — |
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M | -$3.2M | — |
| Interest expense | — | — | — | $63.6K | $45.6K | $197.3K | — |
| Pre-tax income | — | -$12.3M | -$7.8M | -$9.6M | -$7.9M | -$3.2M | — |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M | -$3.2M | — |
| EPS, basic | -8.16 | -80.32 | -39.99 | -13.92 | -2.43 | -1.69 | — |
| EPS, diluted | -8.16 | -80.32 | -39.99 | — | — | — | — |
| Shares, diluted (wtd. avg.) | 926,192 | 152,974 | 194,928 | — | 4.3M | 1.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.5M | $3.2M | $7.4M | $6.2M | $10.8M | $530.4K | — |
| Total current assets | — | — | — | — | $11.6M | $605.5K | — |
| Property, plant and equipment | — | — | — | — | $0 | $0 | — |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M | $605.5K | — |
| Accounts payable | $460.8K | $808.0K | $866.0K | $496.7K | $515.2K | $104.3K | — |
| Short-term debt | — | — | — | — | $0 | $556.2K | — |
| Total current liabilities | — | — | — | — | $1.5M | $3.8M | — |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922.6K | $1.5M | $3.8M | — |
| Retained earnings | -$73.2M | -$65.7M | -$53.4M | -$45.6M | -$36.0M | -$28.1M | — |
| Total equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M | -$3.2M | -$210.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M | -$4.0M | — |
| Stock-based compensation | $143.7K | $657.6K | $522.1K | $930.3K | $1.9M | $0 | — |
| Financing cash flow | $12.1M | $6.9M | $7.6M | $4.3M | $16.0M | $2.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012992.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |